Cargando…

[(18)F]fallypride characterization of striatal and extrastriatal D(2/3) receptors in Parkinson's disease

Parkinson's disease (PD) is characterized by widespread degeneration of monoaminergic (especially dopaminergic) networks, manifesting with a number of both motor and non-motor symptoms. Regional alterations to dopamine D(2/3) receptors in PD patients are documented in striatal and some extrastr...

Descripción completa

Detalles Bibliográficos
Autores principales: Stark, Adam J., Smith, Christopher T., Petersen, Kalen J., Trujillo, Paula, van Wouwe, Nelleke C., Donahue, Manus J., Kessler, Robert M., Deutch, Ariel Y., Zald, David H., Claassen, Daniel O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849871/
https://www.ncbi.nlm.nih.gov/pubmed/29541577
http://dx.doi.org/10.1016/j.nicl.2018.02.010
_version_ 1783306123285102592
author Stark, Adam J.
Smith, Christopher T.
Petersen, Kalen J.
Trujillo, Paula
van Wouwe, Nelleke C.
Donahue, Manus J.
Kessler, Robert M.
Deutch, Ariel Y.
Zald, David H.
Claassen, Daniel O.
author_facet Stark, Adam J.
Smith, Christopher T.
Petersen, Kalen J.
Trujillo, Paula
van Wouwe, Nelleke C.
Donahue, Manus J.
Kessler, Robert M.
Deutch, Ariel Y.
Zald, David H.
Claassen, Daniel O.
author_sort Stark, Adam J.
collection PubMed
description Parkinson's disease (PD) is characterized by widespread degeneration of monoaminergic (especially dopaminergic) networks, manifesting with a number of both motor and non-motor symptoms. Regional alterations to dopamine D(2/3) receptors in PD patients are documented in striatal and some extrastriatal areas, and medications that target D(2/3) receptors can improve motor and non-motor symptoms. However, data regarding the combined pattern of D(2/3) receptor binding in both striatal and extrastriatal regions in PD are limited. We studied 35 PD patients off-medication and 31 age- and sex-matched healthy controls (HCs) using PET imaging with [(18)F]fallypride, a high affinity D(2/3) receptor ligand, to measure striatal and extrastriatal D(2/3) nondisplaceable binding potential (BP(ND)). PD patients completed PET imaging in the off medication state, and motor severity was concurrently assessed. Voxel-wise evaluation between groups revealed significant BP(ND) reductions in PD patients in striatal and several extrastriatal regions, including the locus coeruleus and mesotemporal cortex. A region-of-interest (ROI) based approach quantified differences in dopamine D(2/3) receptors, where reduced BP(ND) was noted in the globus pallidus, caudate, amygdala, hippocampus, ventral midbrain, and thalamus of PD patients relative to HC subjects. Motor severity positively correlated with D(2/3) receptor density in the putamen and globus pallidus. These findings support the hypothesis that abnormal D(2/3) expression occurs in regions related to both the motor and non-motor symptoms of PD, including areas richly invested with noradrenergic neurons.
format Online
Article
Text
id pubmed-5849871
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-58498712018-03-14 [(18)F]fallypride characterization of striatal and extrastriatal D(2/3) receptors in Parkinson's disease Stark, Adam J. Smith, Christopher T. Petersen, Kalen J. Trujillo, Paula van Wouwe, Nelleke C. Donahue, Manus J. Kessler, Robert M. Deutch, Ariel Y. Zald, David H. Claassen, Daniel O. Neuroimage Clin Regular Article Parkinson's disease (PD) is characterized by widespread degeneration of monoaminergic (especially dopaminergic) networks, manifesting with a number of both motor and non-motor symptoms. Regional alterations to dopamine D(2/3) receptors in PD patients are documented in striatal and some extrastriatal areas, and medications that target D(2/3) receptors can improve motor and non-motor symptoms. However, data regarding the combined pattern of D(2/3) receptor binding in both striatal and extrastriatal regions in PD are limited. We studied 35 PD patients off-medication and 31 age- and sex-matched healthy controls (HCs) using PET imaging with [(18)F]fallypride, a high affinity D(2/3) receptor ligand, to measure striatal and extrastriatal D(2/3) nondisplaceable binding potential (BP(ND)). PD patients completed PET imaging in the off medication state, and motor severity was concurrently assessed. Voxel-wise evaluation between groups revealed significant BP(ND) reductions in PD patients in striatal and several extrastriatal regions, including the locus coeruleus and mesotemporal cortex. A region-of-interest (ROI) based approach quantified differences in dopamine D(2/3) receptors, where reduced BP(ND) was noted in the globus pallidus, caudate, amygdala, hippocampus, ventral midbrain, and thalamus of PD patients relative to HC subjects. Motor severity positively correlated with D(2/3) receptor density in the putamen and globus pallidus. These findings support the hypothesis that abnormal D(2/3) expression occurs in regions related to both the motor and non-motor symptoms of PD, including areas richly invested with noradrenergic neurons. Elsevier 2018-02-10 /pmc/articles/PMC5849871/ /pubmed/29541577 http://dx.doi.org/10.1016/j.nicl.2018.02.010 Text en © 2018 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Regular Article
Stark, Adam J.
Smith, Christopher T.
Petersen, Kalen J.
Trujillo, Paula
van Wouwe, Nelleke C.
Donahue, Manus J.
Kessler, Robert M.
Deutch, Ariel Y.
Zald, David H.
Claassen, Daniel O.
[(18)F]fallypride characterization of striatal and extrastriatal D(2/3) receptors in Parkinson's disease
title [(18)F]fallypride characterization of striatal and extrastriatal D(2/3) receptors in Parkinson's disease
title_full [(18)F]fallypride characterization of striatal and extrastriatal D(2/3) receptors in Parkinson's disease
title_fullStr [(18)F]fallypride characterization of striatal and extrastriatal D(2/3) receptors in Parkinson's disease
title_full_unstemmed [(18)F]fallypride characterization of striatal and extrastriatal D(2/3) receptors in Parkinson's disease
title_short [(18)F]fallypride characterization of striatal and extrastriatal D(2/3) receptors in Parkinson's disease
title_sort [(18)f]fallypride characterization of striatal and extrastriatal d(2/3) receptors in parkinson's disease
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849871/
https://www.ncbi.nlm.nih.gov/pubmed/29541577
http://dx.doi.org/10.1016/j.nicl.2018.02.010
work_keys_str_mv AT starkadamj 18ffallypridecharacterizationofstriatalandextrastriatald23receptorsinparkinsonsdisease
AT smithchristophert 18ffallypridecharacterizationofstriatalandextrastriatald23receptorsinparkinsonsdisease
AT petersenkalenj 18ffallypridecharacterizationofstriatalandextrastriatald23receptorsinparkinsonsdisease
AT trujillopaula 18ffallypridecharacterizationofstriatalandextrastriatald23receptorsinparkinsonsdisease
AT vanwouwenellekec 18ffallypridecharacterizationofstriatalandextrastriatald23receptorsinparkinsonsdisease
AT donahuemanusj 18ffallypridecharacterizationofstriatalandextrastriatald23receptorsinparkinsonsdisease
AT kesslerrobertm 18ffallypridecharacterizationofstriatalandextrastriatald23receptorsinparkinsonsdisease
AT deutchariely 18ffallypridecharacterizationofstriatalandextrastriatald23receptorsinparkinsonsdisease
AT zalddavidh 18ffallypridecharacterizationofstriatalandextrastriatald23receptorsinparkinsonsdisease
AT claassendanielo 18ffallypridecharacterizationofstriatalandextrastriatald23receptorsinparkinsonsdisease